CircRNA14781 Drives Olaparib Resistance in Ovarian Cancer

Why It Matters

Olaparib resistance limits the clinical benefit of PARP inhibitors, a cornerstone of ovarian cancer treatment; targeting circRNA14781 could restore drug efficacy and guide patient selection.

Key Takeaways

• circRNA14781 overexpressed in resistant ovarian tumors
• Sponges miR‑200c, restoring BRCA1 expression
• Activates homologous recombination, bypassing PARP inhibition
• Silencing restores olaparib sensitivity in cell lines
• Potential biomarker for predicting PARP inhibitor response

Pulse Analysis

PARP inhibitors like olaparib have reshaped the therapeutic landscape for BRCA‑mutated ovarian cancer, yet resistance emerges in a substantial subset of patients, eroding long‑term outcomes. Conventional mechanisms—secondary BRCA reversion, drug efflux, and replication fork protection—only explain part of the clinical picture, prompting investigators to explore non‑coding RNA networks. Circular RNAs, with their covalently closed loops, resist degradation and can modulate gene expression post‑transcriptionally, making them attractive candidates for hidden resistance pathways.

In the latest study, circRNA14781 surfaced as a potent resistance factor. Using RNA‑seq on paired pre‑treatment and post‑progression tumor biopsies, the team documented a three‑fold increase in circRNA14781 levels among olaparib‑non‑responders. Functional assays revealed that circRNA14781 acts as a molecular sponge for miR‑200c, a microRNA that normally suppresses BRCA1 and other homologous recombination genes. By sequestering miR‑200c, circRNA14781 lifts this repression, re‑activating DNA repair and allowing cancer cells to survive PARP inhibition. CRISPR‑mediated knockdown of circRNA14781 restored drug sensitivity in resistant cell lines, while ectopic expression conferred resistance in sensitive counterparts.

The translational implications are twofold. First, measuring circRNA14781 in circulating tumor DNA or exosomes could provide an early warning of impending olaparib failure, enabling clinicians to pivot to alternative regimens before clinical progression. Second, antisense oligonucleotides or small‑molecule inhibitors designed to disrupt circRNA14781‑miR‑200c interactions represent a novel therapeutic avenue to overcome resistance. As the oncology community seeks durable responses, integrating circRNA profiling into precision‑medicine pipelines may enhance patient stratification and extend the life‑extending benefits of PARP inhibitors.